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Introduction
Cardiogenic shock (CS) is the leading cause of death
in patients hospitalized with acute myocardial
infarction (AMI). Early revascularization strategies
and the use of intra-aortic balloon counterpulsation
have improved outcome but the prognosis remains
poor [17, 18]. The SHOCK trial showed a significant
benefit for patients who underwent early revascular-
ization after one-year follow-up. The survival rate
however remains low with 46.7% at 1 year even with
aggressive treatment [18]. Patients at greatest risk of
death can be identified to some degree by using
clinical and hemodynamic data [13]. These determi-
nants of death are complex and interconnected. Be-
sides hemodynamic and clinical factors also
immunological processes likely influence course and
outcome in patients with CS. In acute MI signs of
inflammation are well known and elevated levels of
acute phase reactants have been shown to be associ-
ated with a worse short- and long-term prognosis
[24]. Signs of a systemic inflammatory response such
as fever, leucocytosis and elevated acute phase reac-
tants are frequently observed in patients with MI and
CS. In patients with extensive myocardial infarctions
a pronounced inflammatory response may further
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j Abstract Background Inflammatory response is an important feature
of acute coronary syndromes and myocardial infarction (MI). The
prognostic value of proinflammatory cytokines in patients with acute MI
complicated by cardiogenic shock is unknown. Methods and results In 41
patients admitted with acute MI (age 60 ± 11 years, six females, 19 Killip
class IV) serial plasma concentration of tumor necrosis factor alpha
(TNF-a), interleukin 6 (IL-6) and interleukin 1 receptor antagonist (IL-
1Ra) were measured. Seven patients with cardiogenic shock (CS)
developed a systemic inflammatory response syndrome (SIRS). Patients
with CS—particularly those who developed SIRS—showed significantly
higher cytokine levels than patients with uncomplicated MI. In patients
with CS and SIRS peak levels of IL-1Ra were 223,973 pg/ml, IL-6
252.8 pg/ml and TNF-a 7.0 pg/ml. In CS without SIRS IL-1Ra levels were
19,988 pg/ml, IL-6 109.3 pg/ml and TNF-a 3.8 pg/ml. In uncomplicated
MI peak IL-1Ra levels were 1,088 pg/ml, IL-6 34.1 pg/ml and TNF-a
2.6 pg/ml. Conclusions The inflammation-associated cytokines TNF-a,
IL-6 and IL-1Ra are significantly elevated in patients with MI complicated
by CS when compared to patients with uncomplicated MI. Among shock-
patients IL-1Ra levels are promising diagnostic markers for early
identification of patients developing SIRS, heralding a poor outcome.
j Key words interleukins – inflammation – infarction – prognosis –
shock
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complicate the clinical course [19]. The associated
clinical findings may be fully compatible with a sys-
temic inflammatory response syndrome. The hemo-
dynamic response to a systemic inflammatory
response syndrome (SIRS) is particularly detrimental
in this setting the setting of AMI. The release of
proinflammatory cytokines like interleukin 1 (IL-1),
interleukin 6 (IL-6) and tumor necrosis factor alpha
(TNF-a) is known to play a pivotal role in the
development of SIRS [32]. We examined the inflam-
matory response of patients with uncomplicated MI
and acute MI with cardiogenic shock by measuring
plasma levels of IL-6, TNF-a and interleukin 1
receptor antagonist (IL-1Ra). A main aspect of our
study was to determine whether the elevation of
proinflammatory cytokines allows to identify patients
who are developing SIRS early on in the course of
disease.
Methods
j Patient population
This prospective study consisted of a cohort undergo-
ing acute percutaneous coronary intervention for AMI
which was enrolled in the years 2001–2003. The study
group comprised 41 consecutive patients presenting
with AMI within 24 h after the onset of chest pain. The
diagnosis of AMI was based on a history of acute chest
pain lasting for more than 30 min and persistent ST
segment elevation on the ECG. Transmural infarction
was confirmed by serial electrocardiographic abnor-
malities, with the development of Q waves lasting 0.04 s
or longer as well as typical rise and fall in levels of
cardiac markers (e.g., CK, CKMB, troponin I and
myoglobin). In all patients acute coronary angiography
revealed an occluded coronary artery that was suitable
for recanalization by PTCA and all patients were suc-
cessfully treated with angioplasty. All 41 patients
underwent acute percutaneous coronary intervention
(PCI) with successful recanalization and stenting of the
infarct related vessel. The ejection fraction was mea-
sured in 29 patients invasively by levocardiography
after PCI and in 12 patients by transthoracic echocar-
diography, measured within 12 h after admission. All
patients survived the first 48 h.
The patients were divided into three groups
according to clinical and hemodynamic findings:
group 1 included 22 patients with uncomplicated
AMI, group 2 comprised 12 patients with AMI com-
plicated by CS (within 36 h after admission) and
group 3 seven patients who developed SIRS within
24 h after AMI with CS. Shock patients were taken
consecutively. Patients in group 1 were chosen pro-
spectively for comparison and matched for sex, age,
and infarct localization from the prospective registry
which included all patients with acute myocardial
infarction.
Nineteen of the patients enclosed were in shock by
clinical and hemodynamic criteria. The clinical cri-
teria were hypotension (systolic blood pressure of
<90 mmHg for at least 30 min or the need for sup-
portive measures to maintain a systolic blood pres-
sure of >90 mmHg) and end-organ hypoperfusion
(cool extremities or a urine output of <30 ml per h,
and a heart rate of >60 beats per min). The hemo-
dynamic criteria were a cardiac index of no more than
2.2 l per min per square meter of body surface area
and a pulmonary-capillary wedge pressure of at least
15 mmHg. A systemic inflammatory response was
definded by >2 of the following conditions: temper-
ature >38C or <36C, heart rate >90 beats/min,
respiratory rate >20 breath/min or PaCO2 < 32 torr
(<4.3 kPa), white blood cell count >12,000 cells/mm3,
<4,000 cells/mm3 or >10% immature (band) cells. A
heart rate above 90 (and not above 100) beats/min
was chosen for the definition of SIRS in the present
study because heart rate is usually influenced by age,
sedation, and pre-interventional therapy with beta-
blockers. In every patient standard intensive care was
performed which included the implantation of an
intra-aortic balloon pump if it was feasible (not lim-
ited by vessel access problems). Especially no specific
measures were taken to modulate an inflammatory
response (non-steroidal anti-inflammatory drugs,
steroids).
The exclusion criteria were a history of a chronic
inflammatory disease, evidence of bacterial infection
based on clinical or laboratory findings (fever
>38.5C; CRP > 50; obvious local infection, e.g., ab-
scess, positive blood cultures during the hospital
course), history of cardiac surgery, severe trauma,
burns or acute pancreatitis within the past four weeks,
immunosuppression or malignancies. The study was
approved by the local Ethics Committee and written
informed consent was obtained from patients or from
their closest relatives.
j Blood collection
The first blood sample was taken before PTCAPCI.
During the revascularization procedure further
blood samples were obtained hourly in the catheter
laboratory and after the patient was transferred to
the intensive care unit (ICU) two-hourly until peak
CK-MB was reached. The inflammatory response
was assessed by measuring TNF-a, IL-6, IL-1Ra and
C-reactive protein (CRP). Cardiac markers including
CK, CK-MB, troponin I and myoglobin were
checked simultaneously with these immunological
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markers to give an estimate of the myocardial cell
damage.
j Laboratory assays
Plasma samples for cytokines were stored at )20C
prior to analysis. IL-1Ra, IL-6 and TNF-a were mea-
sured by commercially available assays (Quantikine,
R&D Systems, Minneapolis, Minnesota). Cardiac en-
zymes and CRP were measured immediately by
standard laboratory techniques.
The upper normal level for IL-1Ra was 598 pg/ml
(mean 291 ± 154 pg/ml), for IL-6 4.5 pg/ml (mean
1.9 ± 0.6 pg/ml) and for TNF-a 1.86 pg/ml (mean
0.95 ± 0.46 pg/ml).
j Statistical analysis
Because data were not distributed normally, non-
parametric tests were used. Results are expressed as
mean ± standard deviation or median as appropri-
ate. For continuous variables the Mann–Whithney U
test was used to evaluate differences among groups.
For categorical variables, a v2 test was used. A
probability value of p < 0.05 was assumed to be
significant.
Results
j Patient characteristics
The three groups did not differ with respect to age,
BMI and success rate of revascularization (Table 1).
In the three groups delay between onset of symptoms
and time of revascularization did not differ signifi-
cantly. Patients with CS and SIRS showed a trend
towards a longer delay between onset of symptoms
and time of recanalization. This difference, however,
was not statistically significant (Table 1). Final TIMI
flow was comparable in all three groups (Table 1).
With the exception of myoglobin and CK in group
3, cardiac markers were only modestly elevated at
baseline (Table 2). The median peak plasma CK
concentration of all patients was 2,845 IU/l, with
higher levels found in group 2 (3,236 IU/l) and group
3 (7,248 IU/l) expressing the larger extent of myo-
cardial damage in these groups (Table 3). The three
groups did not differ with respect to age, BMI and
success rate of revascularization. The left ventricular
ejection fraction was significantly lower in group 3
(CS and SIRS, 24 ± 7%) than in group 1 (LVEF
53 ± 16%) and group 2 (LVEF 44 ± 17%), respec-
tively (uncomplicated AMI). Systolic function did not
differ between patients with cardiogenic shock with-
Table 1 Patient’s demographic and angiographic characteristics
All patients Group 1 Group 2 Group 3
(n = 41) (n = 22) (n = 12) (n = 7)
Mean age y 60 ± 11 57 ± 12 64 ± 9 59 ± 9
Gender M/F 35/6 20/2 9/3 6/1
Body mass index kg/m2 27 ± 4 27 ± 4 25 ± 3 28 ± 3
Cardiovascular risk factors n
Family history 13 9 3 1
Hypercholesterolemia 27 15 8 4
Diabetes mellitus 11 5a 2 4
Hypertension 16 6 6 4
Smoking 30 15 10 5
Location of myocardial infarction n
Anterior 24 16 5b 3
Inferior 17 5 7 5
Right-heart involvement 5 1 3 1
Ejection fraction % 46 ± 18 53 ± 16c 44 ± 17c 24 ± 7
Angiography n
Single-vessel disease 15 11 3 1
Multi-vessel disease 26 11 9 6
Time to recanalization min 460 ± 392 407 ± 367 391 ± 252 767 ± 588
Final TIMI flow
0 0 0 0 0
1 1 0 1 0
2 2 1 2 0
3 37 21 9 7
No reflow 1 0 1 0
a Group 1 vs. group 2, p = 0.026
b Group 2 vs. group 3, p = 0.012
c Group 1 vs. group 3, p = 0.0008; group 2 vs. group 3, p = 0.03
Table 2 Cardiac markers and cytokine levels at baseline
Markers Group 1 Group 2 Group 3 p-values
n = 22 n = 12 n = 7 1 vs. 2 1 vs. 3 2 vs. 3
CK IU/l 488 224 1,508 0.7 0.11 0.13
CKMB IU/l 61 46 303 0.7 0.04 0.05
Troponin lg/l 1.3 1.0 3.8 0.8 0.15 0.12
Myoglobin nmol/l 7.8 14.1 126 0.3 0.0008 0.09
IL-1Ra pg/ml 590 887 73,628 0.03 <0.0001 0.001
IL-6, pg/ml 12.8 33.4 93.5 0.08 0.0003 0.09
TNF-a pg/ml 1.8 1.7 3.5 0.4 0.0024 0.08
CRP mg/l 4.0 10.0 15.0 0.02 0.06 0.7
Data are presented as medians of baseline values
Table 3 Peak cardiac markers and cytokine levels
Markers Group 1 Group 2 Group 3 p-values
n = 22 n = 12 n = 7 1 vs.2 1 vs.3 2 vs.3
CK IU/l 2,448 3,236 7,248 ns 0.032 ns
CKMB IU/l 292 289 1,059 ns 0.017 0.023
Troponin lg/l 37.2 18 58 ns ns 0.063
Myoglobin nmol/l 31.9 128.5 368 0.066 0.003 ns
IL-1Ra pg/ml 1,088 19,988 223,973 0.0006 <0.0001 0.0005
IL-6 pg/ml 34.1 109.3 252.8 0.0026 0.0008 ns
TNF-a pg/ml 2.6 3.8 7.0 0.037 0.012 ns
CRP mg/l 35 102 189 0.057 0.007 0.052
Data are presented as medians of peak values
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out SIRS, and patients with uncomplicated MI (Ta-
ble 1). None of the patients in group 1 and only one
patient in group 2 died during hospitalization. In
group 3 the in-hospital-mortality was 71%.
j Cytokine concentrations
The baseline, serial, and peak plasma concentrations of
proinflammatory cytokines IL-1Ra, IL-6 and TNF-a are
shown in Fig. 1 and Tables 2 and 3, respectively.
j IL-1Ra
Among all inflammatory markers measured, the
plasma concentrations of IL-1Ra showed the most
impressive changes. A rise and fall of plasma levels
can be observed particularly in patients with cardio-
genic shock. Peak plasma concentrations in these
patients are found 1–4 h after admission (Fig. 1).
In group 1, the median peak value of IL-1Ra was
with 1,088 pg/ml (range 438–26,379 pg/ml) substan-
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Fig. 1 Peak concentrations and reference values of IL-1Ra, IL-6 and TNF-a (in picograms per milliliter) for each patient. Patients are grouped based on clinical
presentation as uncomplicated acute MI, acute MI with cardiogenic shock, and MI with cardiogenic shock and SIRS
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tially lower than in group 2 (19,988 pg/ml; range 765–
74,379 pg/ml; p = 0.0006) and group 3 (223,973 pg/
ml; range 73,628–300,000 pg/ml; p < 0.0001).
Shock patients who developed SIRS showed an IL-
1Ra response significantly higher than patients in CS
without SIRS (223,973 pg/ml versus 19,988 pg/ml;
p = 0.0005) (Table 3). IL-1Ra was the only parameter
discriminating clearly between these two groups.
When comparing the first IL-1Ra level upon admis-
sion of all patients in cardiogenic shock, a significant
difference with higher levels found in patients who
later were developing SIRS was noted (73,628 pg/ml
versus 887 pg/ml; p = 0.001). This laboratory finding
preceded the clinical findings defining a systemic
inflammatory response syndrome.
j IL-6 and TNF-a
IL-6 and TNF-a concentrations showed similar pat-
terns in the three patient groups. Both of these cyto-
kines were expressed to a lower extent in patients with
uncomplicated MI (see Table 3). Peak IL-6 levels of
group 1 were with 34 pg/ml significantly lower when
compared to group 2 (109 pg/ml, p = 0.0026) or
group 3 (253 pg/ml, p = 0.0008). The lowest TNF-a
concentrations were likewise found in hemodynami-
cally stable patients (group 1: 2.6 pg/ml). In com-
parison, the values for TNF-a were significantly
higher in group 2 (3.8 pg/ml; p = 0.037) and group 3
(7.0 pg/ml, p = 0.012). Neither IL-6, nor TNF-a
expression was significantly different in shock pa-
tients without or with SIRS (group 2 versus group 3;
Table 3).
j CRP
The production of C-reactive protein in the liver is
mainly induced by IL-6. The CRP-measurements
generally showed higher values in more severely
compromised patients. In group 1 the mean CRP-level
was 35 mg/l, in group 2 102 mg/l and in group 3
189 mg/l. A trend towards stronger CRP-induction in
sicker patients is evident. However, only the com-
parison of CRP concentration in group 1 and group 3
reaches statistical significance.
Discussion
Our study gives insight into inflammatory cytokine
expression in patients with AMI complicated by CS as
compared to patients with uncomplicated MI. Among
the inflammatory markers measured, IL-1Ra was the
parameter that correlated best with severity of dis-
ease. The peak concentration of IL-1Ra in patients
with CS and SIRS exceeded those of patients with
uncomplicated MI more than a hundred-fold. Among
patients with CS there was a close correlation between
the plasma concentration of proinflammatory cyto-
kines and the clinical manifestation of a systemic
inflammatory response syndrome. Moreover, an
analysis of the IL-1Ra concentrations on admission
demonstrates significantly higher initial IL-1Ra levels
in patients who ultimately developed SIRS. Hence IL-
1Ra was a particularly reliable indicator for poor
outcome among shock patients.
j Cytokines measurements in ischemic heart disease
and cardiogenic shock
IL-1 is a prototypic proinflammatory cytokine with a
wide range of actions both systemically and on car-
diovascular level. The IL-1 family encompasses IL-1a,
IL-1b and IL-1Ra and is mainly produced by mono-
cytes and macrophages, and to a lesser degree by
endothelial cells. IL-1Ra is a pure receptor antagonist
of IL-1a/b and has no other known biological activity.
The immunologically active members of the IL-1 gene
family IL-1a and IL-1b are potent proinflammatory
cytokines. However, IL-1a and IL-1b lack a signal
peptide and they are not readily secreted to the sys-
temic circulation and therefore plasma level deter-
minations are unreliable [5]. Both properties are
fulfilled for IL-1Ra, and its production is increased by
the same stimuli as IL-1a and IL-1b. This makes IL-
1Ra a reliable surrogate marker for the action of the
IL-1 family [8, 12]. IL-1 is an endogenous pyrogen
and some of its functions are similar to TNF-a. IL-1
induces the production of nitric oxide, leukotriene
and platelet activating factor [23]. Besides these
mediators with impact on endothelial function there
is an activation of gene expression for clotting factors,
inhibition of fibrinolysis, endothelial passage of neu-
trophils and induction of endothelial adhesion mole-
cules [23]. These mechanisms are believed to
contribute greatly to the pathogenesis of acute myo-
cardial ischemia. Hypoxia has been shown to increase
the production of IL-1 and TNF-a by mononuclear
cells [11]. It can be assumed that extensive ischemic
myocardial damage leads to local production and
direct cardiac release of proinflammatory cytokines
[16, 24].
IL-6 is a cytokine related to IL-1. The production of
IL-6 from macrophages is induced by IL-1 and TNF-a.
Endothelial cells are capable to produce IL-6 on
stimulation with a variety of inflammatory mediators
[21]. IL-6 levels have been shown to be undetectable
in healthy volunteers (<3 pg/ml) but are elevated with
infections and inflammation [4]. High IL-6 levels are
associated with poor outcome in different disease
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processes including unstable angina and septic shock
[4, 6]. IL-6 acts on hepatic cells to produce acute-
phase proteins like fibrinogen, a-2-macroglobulin,
serum amyloid A protein and C-reactive protein. A
strong correlation has been shown between IL-6 and
CRP-levels [27]. IL-6 per se has no direct proinflam-
matory properties, although it is found in infection
and inflammation. Unlike IL-1a/IL-1b and TNF-a
injection of IL-6 into humans is not associated with
hypotension or systemic symptoms. IL-6 has proco-
agulant properties which may influence the course of
acute coronary syndromes [31]. In acute MI IL-6
levels were found to be elevated on admission, before
reperfusion by PCI and even before the appearance of
detectable signs of necrosis [24]. As a conclusion of
these findings a primary role of IL-6 in the patho-
genesis of acute MI has been suggested [24].
TNF-a is polypeptide with hormone-like proper-
ties. A large variety of activities of this cytokine are
involved in the defense against pathogenic microor-
gansims and the process of tissue repair [2]. TNF-a
derives from leukocytes/macrophages and not from
endothelial cells [21]. Elevated TNF-a levels were
found repeatedly in patients with advanced congestive
heart failure [15, 20, 29]. Moreover, experimental
studies have shown that TNF-a has a cardiotoxic ef-
fect and can produce cardiomyopathy, left ventricular
remodeling and pulmonary edema [14, 22, 28]. In
acute MI significant changes in TNF-a levels were
mainly associated with extensive myocardial damage,
signs of heart failure and the presence of rhythm
disturbances [16, 30]. When comparing TNF-a levels
in blood of the coronary sinus and the aorta in pa-
tients with acute MI, there was no significant tran-
scardiac gradient found [24]. It was concluded, that
the number of leukocytes entrapped in the coronary
circulation may be too small to generate detectable
transcardiac TNF-a gradients. However, this finding
does not exclude a paracrine release from these leu-
kocytes and macrophages which may stimulate the
endothelial production of IL-6.
The inflammatory reaction induced by proinflam-
matory cytokines has been described as a cascade of
gene products which are not found in healthy persons
[7]. IL-1 and TNF-a are particularly effective in acti-
vating this cascade in a synergistic manner. Anti-
inflammatory cytokines such as IL-4, IL-10, IL-13 and
transforming growth factor (TGF)-b suppress the
intensity of this cascade [3]. An imbalance between
pro-inflammatory and anti-inflammatory cytokines
leads to a poorly antagonized acceleration of the
inflammatory cascade. It is conceivable that an over-
whelming pro-inflammatory response—possibly pre-
cipitated by extensive myocardial ischemia—with
extraordinary high levels of IL-1 is the starting point
of such a process. Another possible mechanism as a
triggering factor of this cascade is an extensive myo-
cyte damage due to reperfusion injury. The deleteri-
ous effects not only on endothelial level but also on
the hemodynamic response may well explain the poor
outcome of patients with these extremely high levels
of plasma IL-1Ra, IL-6 and TNF-a.
j Previous studies
The inflammatory mechanism involved in acute cor-
onary syndromes and myocardial necrosis were
studied in some selected patient populations. Biasucci
demonstrated not only the elevation of IL-6 in
unstable angina but also the prognostic impact of
cytokine levels in the course of hospitalization [3, 4].
In this study patients with unstable angina and with a
complicated hospital course had higher cytokine lev-
els on admission. A fall of IL-1Ra and IL-6 48 h after
admission was associated with an uneventful course.
Neuman found in patients with acute MI before
and after recanalization significantly elevated con-
centrations of IL-6 in the coronary sinus blood
compared with the arterial blood [24]. This sophisti-
cated technique demonstrated for the first time car-
diac release of IL-6 in acute MI. It was speculated that
the vascular endothelium was the predominant source
of this cardiac IL-6. The possibility of a primary role
of IL-6 in the pathogenesis of MI has been suggested.
Furthermore, the possibility of important systemic
effects should be assumed if cardiac liberation of IL-6
is ongoing [1].
The relative increase in TNF-a has been suggested
as a reliable method of assessing the severity of
myocardial damage after acute myocardial infarction
[16]. In patients with septic shock high levels of IL-6
were found to be a particularly poor prognostic sign
[6].
j Study limitations
The number of patients in this single center pilot
study is relatively low, reflecting also the difficulties in
enrolling patients with a life-threatening condition.
However, the analysis of our data is based on clearly
predefined categories of patients with acute myocar-
dial infarction. In addition, the treatment modality is
homogenous throughout the whole study population,
with every patient undergoing acute PCI. No data
exist regarding the time frame of rise and fall of
cytokine levels in this particular clinical setting. Fur-
thermore, negative blood cultures were an exclusion
criteria for coexisting sepsis. With respect to sepsis,
blood cultures are poor markers because they are not
positive in all patients. However, the present study
was carried out at a period when procalcitonin mea-
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surements were not performed at our institution, to
define infection more precisely. Finally, prognosis of
patients with cardiogenic shock is determined by
several clinical parameters [25] and the development
of multiorgan dysfunction [19] which can be deter-
mined by the calculation of several scores (e.g.,
APACHE, SAPS, SOFA). These scores, however, were
not performed at our institution at the time of the
study protocol and to calculate these scores retro-
spectively makes them prone to error.
j Clinical perspectives
The role of cytokines in heart disease is subject of
increasing interest. Many clinical investigations have
focused on cytokines in heart failure or the patho-
genesis of arteriosclerosis. The main aspect of our
study was to assess a subset of patients with AMI and
cardiogenic shock and a particularly poor outcome
due to a systemic inflammatory response. These pa-
tients did not differ from other patients in cardiogenic
shock in regard to their demographic data, the infarct
size, the infarct localization or treatment. The one
important difference was a lower left ventricular
ejection fraction in patients with cardiogenic shock
and SIRS. The most important indicator for poor
outcome was a markedly increased IL-1Ra levels,
which were present already upon admission. In these
patients the mortality rate was extremely high despite
immediate and successful revascularization followed
by aggressive supportive treatment. Whether IL-1 is
just an indicator for poor outcome or in fact a con-
tributing factor cannot be determined by our study.
One experimental approach to provide evidence of the
causal role of this particular cytokine would be its
specific blockade or neutralization. Antibodies direc-
ted against TNF-a and IL-1 were used in patients with
rheumatoid arthritis and Crohn’s disease with few
side effects [9, 10, 26]. In view of the poor prognosis
of the patients with cardiogenic shock further com-
plicated by SIRS, future studies should focus not only
on the possible pathogenesis of this condition but also
on possible therapeutic approaches on immunological
level.
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